

LifeSci Biotechnology Clinical Trials Index

2/17/2023

Effective at the market close on Tuesday, February 21, 2023, **CINC** will be removed from the **LifeSci Biotechnology Clinical Trials Index** and its value will be redistributed to the remaining index components based on their weights.

- On January 9, 2023, CinCor Pharma, Inc. announced that it would be acquired by AstraZeneca for \$26.00/share in cash plus a non-tradeable contingent value right of up to \$10.00. The tender offer is expected to expire in late February 2023.